tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Prelude Therapeutics Reports Q3 2025 Financial Results
PremiumCompany AnnouncementsPrelude Therapeutics Reports Q3 2025 Financial Results
2M ago
Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year
Premium
The Fly
Prelude Therapeutics reports Q3 EPS (26c) vs. (43c) last year
2M ago
Prelude Therapeutics sees cash runway into 2027
Premium
The Fly
Prelude Therapeutics sees cash runway into 2027
2M ago
Prelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs
PremiumThe FlyPrelude to prioritize JAK2V617F JH2 inhibitor, KAT6A selective degrader programs
3M ago
Prelude Therapeutics pauses development of SMARCA2 degrader program
Premium
The Fly
Prelude Therapeutics pauses development of SMARCA2 degrader program
3M ago
Prelude Therapeutics sees cash runway into 2027
Premium
The Fly
Prelude Therapeutics sees cash runway into 2027
3M ago
Prelude Therapeutics appoints Katina Dorton to board of directors
PremiumThe FlyPrelude Therapeutics appoints Katina Dorton to board of directors
3M ago
Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
Premium
Ratings
Prelude Therapeutics: Promising SMARCA2-Targeted Degraders and Positive Outlook Support Buy Rating
4M ago
Prelude Therapeutics Regains Nasdaq Compliance
Premium
Company Announcements
Prelude Therapeutics Regains Nasdaq Compliance
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100